Mouse Models of Human Neurodegenerative Disorders

1 February 2005

journal article
review article
Published by American Medical Association (AMA) in Archives of Neurology

Vol. 62 (2) , 185-187
https://doi.org/10.1001/archneur.62.2.185

Abstract

Central nervous system diseases constitute a major target for drug development. Transgenic mouse models, in which genes identified in familial forms of human brain diseases are expressed in mouse neurons and glia, offer opportunities to detect and follow pathologic progression and provide potential biomarkers by which to assess therapeutic interventions. Evidence for Alzheimer disease suggests some starting requirements for the experimental data that could enhance the likelihood of developing medications in these mouse models that would also be effective in humans.

Keywords

This publication has 9 references indexed in Scilit:

Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: Digital morphometric analyses
Proceedings of the National Academy of Sciences, 2004
Building a More Perfect Beast
The American Journal of Pathology, 2004
Ultrastructural and behavioural changes precede amyloid deposition in a transgenic model of Alzheimer’s disease
Neuroscience, 2003
Amyloid deposition in the hippocampus and entorhinal cortex: Quantitative analysis of a transgenic mouse model
Proceedings of the National Academy of Sciences, 2003
Of mice and men: Reconciling preclinical ALS mouse studies and human clinical trials
Annals of Neurology, 2003
Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: A magnetic resonance microscopy and stereologic analysis
Proceedings of the National Academy of Sciences, 2003
Does my mouse have Alzheimer's disease?
Genes, Brain and Behavior, 2002
Neuropathological Characterization of Mutant Amyloid Precursor Protein Yeast Artificial Chromosome Transgenic Mice
Neurobiology of Disease, 2001
Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP
Science, 2001